JP2002503676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002503676A5 JP2002503676A5 JP2000531476A JP2000531476A JP2002503676A5 JP 2002503676 A5 JP2002503676 A5 JP 2002503676A5 JP 2000531476 A JP2000531476 A JP 2000531476A JP 2000531476 A JP2000531476 A JP 2000531476A JP 2002503676 A5 JP2002503676 A5 JP 2002503676A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- disease
- macrophage
- antibody
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002540 macrophage Anatomy 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000009109 Fc receptors Human genes 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WMTIOGUVKBSEOW-UHFFFAOYSA-N ClC1(Cl)OP(=O)OP(=O)O1 Chemical compound ClC1(Cl)OP(=O)OP(=O)O1 WMTIOGUVKBSEOW-UHFFFAOYSA-N 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7496798P | 1998-02-17 | 1998-02-17 | |
| US60/074,967 | 1998-02-17 | ||
| PCT/US1999/003488 WO1999041285A1 (en) | 1998-02-17 | 1999-02-17 | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002503676A JP2002503676A (ja) | 2002-02-05 |
| JP2002503676A5 true JP2002503676A5 (cg-RX-API-DMAC10.html) | 2006-03-30 |
Family
ID=22122724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531476A Pending JP2002503676A (ja) | 1998-02-17 | 1999-02-17 | Ｆｃレセプターのリガンドを使用するマクロファージ媒介性疾患の治療および診断 |
Country Status (15)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756396B1 (en) * | 1997-05-07 | 2004-06-29 | Qlt Inc. | Ethylene glycol esters as photoactive agents |
| IL158532A0 (en) | 2001-05-02 | 2004-05-12 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
| US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| WO2007094776A1 (en) * | 2006-02-15 | 2007-08-23 | William Marsh Rice University | Compositions and methods for suppressing fibrocyte differentiation |
| US20100297074A1 (en) * | 2002-12-23 | 2010-11-25 | Richard Hans Gomer | Wound healing compositions, systems, and methods |
| JP4922560B2 (ja) * | 2002-12-23 | 2012-04-25 | ウイリアム、マーシュ、ライス、ユーニヴァーサティ | 線維細胞への分化の検出方法、線維症を抑制する組成物および方法 |
| US7763256B2 (en) * | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1622646B1 (en) * | 2003-05-06 | 2012-08-08 | Purdue Research Foundation | Treatment of lupus targeting the macrophages or the folate receptor |
| US20050008633A1 (en) * | 2003-05-19 | 2005-01-13 | Advanced Inhalation Research Inc. | Chemical and physical modulators of bioavailability of inhaled compositions |
| BG65715B1 (bg) * | 2003-09-04 | 2009-08-31 | Чавдар ВАСИЛЕВ | Средство за селективно подтискане на патологични днк - специфични в клетки |
| US7057624B2 (en) * | 2003-10-28 | 2006-06-06 | Eastman Kodak Company | Display device light leakage compensation |
| EP1570858A1 (en) * | 2004-03-05 | 2005-09-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| US20100166654A1 (en) * | 2004-12-03 | 2010-07-01 | The Uab Research Foundation | Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery |
| US20060128031A1 (en) * | 2004-12-15 | 2006-06-15 | Robotti Karla M | Addressable recovery of bound analytes from an evanescent wave sensor |
| JP5175723B2 (ja) * | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| US8795633B2 (en) | 2005-09-23 | 2014-08-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| EP2029173B1 (en) | 2006-06-26 | 2016-07-20 | MacroGenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
| JP2010509570A (ja) | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
| JP5220025B2 (ja) | 2006-12-04 | 2013-06-26 | プロメディオール， インコーポレイテッド | 線維症疾患を処置するための併用療法 |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| US8586595B2 (en) | 2007-02-07 | 2013-11-19 | Purdue Research Foundation | Positron emission tomography imaging method |
| WO2008148001A2 (en) | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| SG189730A1 (en) | 2008-04-02 | 2013-05-31 | Macrogenics Inc | Her2/neu-specific antibodies and methods of using same |
| CN106349390B (zh) | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
| PT2405928T (pt) | 2009-03-11 | 2017-02-07 | Promedior Inc | Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade |
| PT2405929T (pt) | 2009-03-11 | 2018-07-23 | Promedior Inc | Métodos de tratamento para distúrbios autoimunes |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| HUE041034T2 (hu) * | 2009-06-17 | 2019-05-28 | Promedior Inc | SAP-variánsok és alkalmazásuk |
| WO2011017791A1 (pt) | 2009-08-10 | 2011-02-17 | Fundação Oswaldo Cruz | Anticorpos monoclonais para a proteína pbp2-a e sequências homólogas para o tratamento de infeçcões e imunodiagnóstico em bactérias do filo firmicutes |
| MX2012004029A (es) | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| KR102006997B1 (ko) * | 2012-07-03 | 2019-08-02 | 한국생명공학연구원 | ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| CN109490540A (zh) * | 2017-09-13 | 2019-03-19 | 中国科学院上海药物研究所 | 单核/巨噬细胞在主动脉损伤中的诊断和治疗应用 |
| CN117757924A (zh) * | 2023-12-25 | 2024-03-26 | 上海市同济医院 | Cd64作为靶点在开发或筛选或制备糖尿病皮肤溃疡预后产品中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4470925A (en) * | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US5635600A (en) * | 1986-07-07 | 1997-06-03 | Trustees Of Dartmouth College | Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes |
| US4869903A (en) * | 1987-05-29 | 1989-09-26 | Genelabs Incorporated | Method of selectively inhibiting HIV |
| US5026557A (en) * | 1987-09-09 | 1991-06-25 | The Liposome Company, Inc. | Adjuvant composition |
| US5840840A (en) * | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
| US5767106A (en) * | 1992-02-21 | 1998-06-16 | Hyal Pharmaceutical Corporation | Treatment of disease and conditions associated with macrophage infiltration |
| US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
| GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| IL111105A (en) * | 1993-09-30 | 2009-05-04 | Univ Pennsylvania | Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis |
| US5578706A (en) * | 1993-11-04 | 1996-11-26 | Board Of Regents, The University Of Texas | Methods and compositions concerning homogenous immunotoxin preparations |
| US5580715A (en) * | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| AU721792B2 (en) * | 1996-09-06 | 2000-07-13 | Medarex, Inc. | Cyanidin compositions and therapeutic and diagnostic uses therefor |
-
1999
- 1999-02-17 CA CA002321136A patent/CA2321136A1/en not_active Abandoned
- 1999-02-17 PL PL99342729A patent/PL342729A1/xx not_active Application Discontinuation
- 1999-02-17 JP JP2000531476A patent/JP2002503676A/ja active Pending
- 1999-02-17 CN CN99805129A patent/CN1307590A/zh active Pending
- 1999-02-17 HK HK02100608.2A patent/HK1038931A1/zh unknown
- 1999-02-17 WO PCT/US1999/003488 patent/WO1999041285A1/en not_active Ceased
- 1999-02-17 KR KR1020007009038A patent/KR20010041010A/ko not_active Ceased
- 1999-02-17 EP EP99908236A patent/EP1056781A1/en not_active Ceased
- 1999-02-17 EA EA200000848A patent/EA200000848A1/ru unknown
- 1999-02-17 IL IL13791999A patent/IL137919A0/xx unknown
- 1999-02-17 SI SI9920025A patent/SI20475A/sl not_active IP Right Cessation
- 1999-02-17 HU HU0100929A patent/HUP0100929A3/hu unknown
- 1999-02-17 US US09/251,570 patent/US20020058284A1/en not_active Abandoned
- 1999-02-17 AU AU27721/99A patent/AU2772199A/en not_active Abandoned
-
2000
- 2000-08-16 NO NO20004098A patent/NO20004098L/no not_active Application Discontinuation
-
2003
- 2003-07-25 US US10/627,307 patent/US20040141967A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Portoles et al. | Monoclonal antibodies to murine CD3 epsilon define distinct epitopes, one of which may interact with CD4 during T cell activation. | |
| JP6294414B2 (ja) | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 | |
| CA2210620C (en) | Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen | |
| US5817310A (en) | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor | |
| Bajtner et al. | Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen | |
| JP4432031B2 (ja) | インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体 | |
| KR20260008160A (ko) | 항인터류킨-17a 항체, 그의 약학 조성물 및 용도 | |
| US20040210040A1 (en) | Amphiregulin antibodies and their use to treat cancer and psoriasis | |
| KR20080031049A (ko) | 항-ανβ6 항체 및 이의 용도 | |
| KR20180048712A (ko) | Tl1a에 특이적으로 결합하는 항체 | |
| BG63549B1 (bg) | Рекомбинантни интерлевкин-4-антитела, използвани за лечение на интерлевкин-4- медиирани неразположения | |
| CA2351887A1 (en) | Psca: prostate stem cell antigen and uses thereof | |
| KR20170036503A (ko) | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 | |
| RS80704A (sr) | ANTI-αvβ6 ANTITELA | |
| CN101903044A (zh) | 对人铁调素具有特异性的抗原结合蛋白 | |
| CA3159465A1 (en) | Humanized cldn18.2 antibodies | |
| JPWO1997002290A1 (ja) | 抗Ｆａｓリガンド抗体および該抗体を用いた測定法 | |
| CA3162773A1 (en) | Tumor-specific claudin 18.2 antibodies | |
| KR102571012B1 (ko) | 항-il-22r 항체 | |
| US20050142137A1 (en) | Antibodies against secretoryleukocyte protease inhibitor | |
| JP6940732B2 (ja) | がん細胞特異的抗ポドカリキシン抗体とその製造方法 | |
| CN120712286A (zh) | 抗体、抗原结合片段和使用方法 | |
| Hamilton et al. | Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies | |
| Poul et al. | Cassette baculovirus vectors for the production of chimeric, humanized, or human antibodies in insect cells | |
| WO2003106478A9 (en) | ANTIBODIES BINDING TO ALPHAE INTEGRIN |